For patients with advanced endometrial carcinoma that is not MSI-H or dMMR, who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation.
Financial Assistance
With the LENVIMA $0 Co-Pay Program, eligible commercially insured patients will pay as little as $0 out-of-pocket for each prescription. Eisai will pay up to a maximum of $40,000 per year to assist with the out-of-pocket costs for LENVIMA.*
*Maximum benefit and eligibility: Depending on the insurance plan, patients could have additional financial responsibility for any amounts over Eisai’s maximum liability. Not available to patients enrolled in state or federal healthcare programs, including Medicare, Medicaid, Medigap, VA, DoD, or TRICARE. Offer only available to patients with private, commercial insurance. See www.LENVIMAREIMBURSEMENT.com for complete terms and conditions.
Accessing LENVIMA
Specialty Pharmacies
LENVIMA is available through 5 Specialty Pharmacies—Accredo®, Biologics, CVS, Onco360, and Optum® that will mail LENVIMA directly to patients.
Physician office/clinic or hospital pharmacies
LENVIMA is also available to eligible in-office and hospital-based pharmacies. Please contact your preferred distributor for more information, including eligibility requirements.
Selected Safety Information for
KEYTRUDA® (pembrolizumab)
PD-1 = programmed death receptor-1; PD-L1 = programmed death ligand 1
Before prescribing KEYTRUDA® (pembrolizumab), please read the accompanying Prescribing Information. The Medication Guide also is available.
Selected Safety Information for
LENVIMA® (lenvatinib)
Adverse reactions led to dose reduction or interruption in 88% of patients receiving LENVIMA. The most common adverse reactions (≥5%) resulting in dose reduction or interruption of LENVIMA were fatigue (32%), hypertension (26%), diarrhea (18%), nausea (13%), palmar-plantar erythrodysesthesia (13%), vomiting (13%), decreased appetite (12%), musculoskeletal pain (11%), stomatitis (9%), abdominal pain (7%), hemorrhages (7%), renal impairment (6%), decreased weight (6%), rash (5%), headache (5%), increased lipase (5%), and proteinuria (5%).
Fatal adverse reactions occurred in 3% of patients receiving LENVIMA + KEYTRUDA, including gastrointestinal perforation, RPLS with intraventricular hemorrhage, and intracranial hemorrhage.
Serious adverse reactions occurred in 52% of patients receiving LENVIMA + KEYTRUDA. Serious adverse reactions in ≥3% of patients were hypertension (9%), abdominal pain (6%), musculoskeletal pain (5%), hemorrhage (4%), fatigue (4%), nausea (4%), confusional state (4%), pleural effusion (4%), adrenal insufficiency (3%), colitis (3%), dyspnea (3%), and pyrexia (3%).
Permanent discontinuation due to adverse reaction (grade 1-4) occurred in 21% of patients who received LENVIMA + KEYTRUDA. The most common adverse reactions (>2%) resulting in discontinuation of LENVIMA were gastrointestinal perforation or fistula (2%), muscular weakness (2%), and pancreatitis (2%).
QTc = corrected QT interval; MRI = magnetic resonance imaging; CNS = central nervous system.
Before prescribing LENVIMA® (lenvatinib), please read the accompanying Prescribing Information and Patient Information.